MoonLake Immunotherapeutics Prices $200M Stock Offering, Shares Fall

By EC Assets · Published 24 June 2026

MoonLake Immunotherapeutics announced the pricing of a public offering of Class A ordinary shares. The offering consists of 9 million shares at a price of $20.00 per share. This public offering amounts to $200 million. MoonLake Immunotherapeutics (MLTX) priced this underwritten public offering. The company stated the offering consists of 9 million Class A ordinary shares. Each share is priced at $20.00. The offering is valued at $200 million. MoonLake Immunotherapeutics is identified by its ticker MLTX. The closure of the offering is anticipated around June 25, 2026. This is subject to customary conditions. MoonLake's stock fell after the pricing announcement. Stock fell after the pricing of the $200 million equity offering. The public offering was described as upsized. This article is intended for informational purposes only. It does not constitute investment advice.